ZBH Zimmer Biomet
FY2024 10-K
Zimmer Biomet (ZBH) filed its fiscal year 2024 10-K annual report with the SEC on Feb 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business model: Medical device design, manufacture, and distribution focused on orthopedic products
- • No new products, services, or segments introduced or emphasized this year
Financial SummaryXBRL
Revenue
$7.7B
Net Income
$904M
Operating Margin
16.7%
Net Margin
11.8%
ROE
7.2%
Total Assets
$21.4B
EPS (Diluted)
$4.43
Operating Cash Flow
$1.5B
Source: XBRL data from Zimmer Biomet FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Zimmer Biomet Annual Reports
Get deeper insights on Zimmer Biomet
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.